<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00532597</url>
  </required_header>
  <id_info>
    <org_study_id>EMCIRB 07-01</org_study_id>
    <nct_id>NCT00532597</nct_id>
  </id_info>
  <brief_title>Effects of On-Line Hemodiafiltration(HDF) on Vascular Health in Chronic Hemodialysis Patients</brief_title>
  <official_title>Effects of On-Line Hemodiafiltration(HDF) on Endothelial Dysfunction in Chronic Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eulji General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eulji General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether on-line hemodiafiltration ameliorate the
      endothelial dysfunction compared with the low flux hemodialysis in end stage renal disease
      patients on maintenance hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. On-line hemodiafiltration(OL-HDF) is a technique that combines diffusion with convection
           in which the large substitution fluid is produced directly from the dialysate. It offers
           many advantages aside from its safe inflammatory profile, which is attributable to the
           use of ultrapure dialysate and highly biocompatible dialysis membranes. Due to an
           improved convective clearance, significantly increased removal of large or protein-bound
           uremic retention solutes can be achieved, with a potential benefit on cardiovascular
           morbidity and mortality.

        2. Endothelial dysfunction, almost universal in end stage renal disease, is important risk
           factor for cardiovascular events, and can be evaluated by brachial artery
           endothelium-dependent vasodilation (flow-mediated dilation) to reactive hyperemia
           following 5 min of forearm ischemia.

        3. The stable HD patients will receive 8-week treatment on OL-HDF or conventional low flux
           HD and then crossed over to opposite treatment arm. The FMD will be measured by one
           sonographer, and at the same time whole blood and serum will be sampled and stored for
           further analysis. The timepoint for measurement is 4-week interval after baseline
           evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial dysfunction measured by flow-mediated vasodilation</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis</condition>
  <arm_group>
    <arm_group_label>O</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>L</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>On-line hemodiafiltration</intervention_name>
    <arm_group_label>O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Low flux hemodialysis</intervention_name>
    <arm_group_label>L</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  end stage renal disease on maintenance hemodialysis for more than 3 months

        Exclusion Criteria:

          -  diagnosis of active cardiovascular diseases in 6 months

          -  elevation of liver enzymes over two fold of upper normal limit in 3 months

          -  admission for acute infection in 3 months

          -  untreatable stenosis of vascular access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SuAh Sung, M.D.,PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, College of Medicine, Eulji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-Hwan Hwang, M.D.</last_name>
    <phone>82-2-970-8457</phone>
    <email>ondahl@eulji.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Su-Ah Sung, M.D., PhD.</last_name>
    <phone>82-2-970-8205</phone>
    <email>soi@eulji.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hwan Hwang, M.D.</last_name>
      <phone>82-2-970-8457</phone>
      <email>ondahl@eulji.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Su-Ah Sung, M.D.,PhD.</last_name>
      <phone>82-2-970-8205</phone>
      <email>soi@eulji.ac.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2007</study_first_submitted>
  <study_first_submitted_qc>September 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2007</study_first_posted>
  <last_update_submitted>September 19, 2007</last_update_submitted>
  <last_update_submitted_qc>September 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2007</last_update_posted>
  <keyword>Vascular Endothelium-Dependent Relaxation</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Hemodiafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 29, 2009</submitted>
    <returned>February 24, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

